Financial XXXX And Thank welcome Sasha. and you, Third to Quarter Business Update. our
Our clinical fronts. diligently teams and commercial, throughout on regulatory continued the legal quarter to work
As and track to acute weeks ganaxolone Trials R&D chronic need, both limit across oral indications, and the I will is news remain franchises to since initial continued setting. recent in few it's remarks been day, my items. our in there where high our our as most only we on both IV a corporate medical multiple advance unmet
and this in patent In discuss strategy, addition, and front shortly. I advocacy regulatory our to meaningful detail exclusivity progress which the achieved further with make centric patient we on advances continued quarter, important will
for associated being under CDD. validated announce agency to The application treatment of assessment. that seizures medicines pleased with has We the the accelerated application marketing authorization for European ganaxolone is evaluated are the
granted delighted the the result, expected commission tuberous now share the XXXX Europe. orphan ganaxolone CHMP oral ganaxolone in quarter. complex. in orphan disease early the of officially the third TSC quarter and commission sclerosis CDD and to been for a decision in granted opinion drug We're U.S. to designation and in European We've in that has status also As second European the both is
we orphan granted IV status United a disease States. As status ganaxolone were in the in reminder, for epilepticus refractory previously
additional Let the growing color the momentum some briefly for add IV and highlight franchise. me
recruiting seen the activation X were in XX result have improvements trial added We several in sites epilepticus other which a the refractory site currently COVID-XX second sites Phase after now We continued status of of RAISE and pandemic. have for impacts activated, six resource challenges of the direct quarter, see allocations challenges excitement in of the facing October. our by program. pleased would to focused in on counter ability operations We're their caused key the to our some share and to like month clinical of critically they as objectives. difficult other remain I diligently pandemic the team, advancing corporate this the success important XX of growing
readiness working We with reach as commercial in been ganaxolone union. actively and the on as patients second We've more pro-drugs the are around world. collaborating generation they prepare opportunities to as of extensively team the exploring Orion European well ganaxolone’s formulations
opportunity a In believe global was addition, that for franchise. there we ganaxolone greater the
December future organization a equally focus why current ganaxolone of to example continue single busy is month will access rapidly that And For the approximately have example, the our are with improving is XXX there and with will patients the CDKLX discussions China, families we on Alliance indications. of in lead learned the just considered active. have Alliance been the in our in with for an be This adoption team. and registered of testing. that genetic number its XX to global growing those
breaker accepted at we've We including will had nine abstracts, XXXX a presentation. have presence American meeting, annual where the a late strong society epilepsy for
for event and virtual Monday, We analysts are X. during host the investors December on meeting to a planning
Before Narrowness We our therapeutic is the turning additional in focused overall safety review that and epilepsies. strategy treatment Joe, on a me believe our strong thoughts. the novel few call limited its the indication, and that CDKLX is options. the other and have over let of quickly of it deficiency of differentiates to rare disorder potential efficacy profile mechanism treatment CDD lead action, encouraging in refractory epilepsies ganaxolone
it We with have PDUFA CDKLX and scheduled filed oral action indication, bleed March. target dates have FDA ganaxolone the in and
has name final ZTALMY. We to established have registered recently revealed trademark approval. our also name the and been This trade subject proposed brand FDA is
medical We of have CDD the who across actively place a fully United are engaging medical in the centers team excellence at liaison community science staffed States.
expand remarks. continues key be and Shafer, the expected majority prepare Officer of from highlights XXXX sharing to launch FDA our to following our DEA the continued we'll pre-commercial Steve team Chief quarter in Our commercial his Christy Commercial and scheduling our vast approval leaders some of team of for with place. in ganaxolone. the mid
of additional our States, will expect United an in role ganaxolone voucher, a is ganaxolone ganaxolone both receive we the a financial in approved reminder central important in establish is following to of One and ensure commercially goal if a management longterm play rare to disease U.S. bolstering approval York. which for as New comprehensive and next CDD year available CDD potential the treatment pediatric to the Our the in is position. pillar
development toward move me strategy. Let
We of to series to undertaking several ganaxolone trials investigate clinical in are indications. a committed new
that be first tuberous complex. first ready initiate Trial XXXX. of in X our with TrustTSC in the sclerosis XXXX with of a to expected are first The expected data quarter to of We half early in registration patient the program enrolled Phase from trial the
Joe meet remarks. review the his already from that the exceed Phase will to key learnings X our details timelines. is X study team design and working those in the Phase or diligently Our prepared
can prevent three anesthetics that future the distinct from suffering and treatment escalation number improve Turning believe epilepticus success. will significant back of play patients. are in There to franchise, role in of of dramatically to trials our outcomes IV ganaxolone status we the patients IV a a
trial X to continues refractory expect Our half in we advance, in complete RAISE to trial epilepticus this status of Phase the second and XXXX.
patient remains the year. the approval IV study first critical as trial trial, process, but population. track, serve enrollment a European three ability has ganaxolone to phase the piece This next anticipate in only we on and in II the the patient of of will of half U.S. potential not begin second RAISE use to broaden Our
which Our third epilepticus, the in established refractorySE, status focused trials, status trial which focused contrast the anticipate in continuum. status enrollment XXXX. on begin half first occurs is to early RAISE is U.S. on We the trial. And to RESET the RESET are in of
to continue nicely. programs formulation new our Finally, progress
a generation formulation an a and improved develop titration physicians. is goals including better clinical with broader profile, our second of One for bioavailability schedule
half be that volunteers of expect formulation We will XXXX. healthy with in the our first new dosed
Our CMC to have team working and future of strategic franchise. together coordinate help operations generation been our clinical the next
should the a middle year. of enter second that Phase next have candidate X by We
this quickly of focusing XXXX, oral also first expected Syndrome half demonstrate the efforts Phase PK in profile, Lennox-Gastaut second move shortly. we begin If to study will sustained a Joe to detail the II trial are half We of to a a plan on research that in the greater new developing topic formulation. discuss formulation expect and XXXX. in of studies in release would
our for been method intellectual making specifies great of our and we granted use Beyond new patent ganaxolone enhancing our a and IV method our strides, We've trials, a advocacy dosing strengthening clinical which were recently of property XXXX. efforts. IP. franchise, our treatment expect efforts. that investment newly we regard supported and And to in advocacy patent With IV epilepticus believe we status issued expires is in to the continue the which by
work. view orphan Our that is matters, particularly patient every disease rare in and
help to pharmaceutical details a Joe. engage, study forces history natural organizations of biotech their assessments is Loulou advocacy I of educate, to empower that community. the goal and will the six patients CDD. foundation Our undertake we've joined utility leave and To caregivers, observational and to patients, the families, key and other the in end, to collaboration the with and various understand clinical better the with
foundation privileged disorder this scientific are CDD the be knowledge improve the community. support partnering the to an We effort Loulou in about to serious and with
over Joe call some would Now, turn additional for I comments. to to like the
